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With great interest we read the paper of Khalil and L¨ aer
on the concepts of physiologically based pharmacokinetic
(PBPK) modeling and its applications to pediatric drug
development [1]. The authors clearly described the method-
ology, applications, and limitations of PBPK models in
pediatric drug development [1]. In essence, PBPK models
hold the promise to design and perform a pediatric study
based on “a well-educated guess” to paraphrase what the
authors refer to as “conﬁrmatory” instead of “exploratory”
approach. The approach described by the authors hereby
mainly reﬂects what we would like to describe as a “top-
down (from model to clinical observations)” concept: based
on the available knowledge on developmental anatomy and
physiology, a PBPK model is developed, undergoes valida-
tion, and willsubsequentlyfacilitate pediatric studies [1].We
would like to further challenge research groups active in the
ﬁeld of PBPK modeling not to get too disconnected from
the“invivo”worldofpediatricdevelopmentalpharmacology
and also consider what we would like to describe as a
“bottom-up (from clinical observations to model)” concept:
from compound speciﬁc observations to mechanism-based
models[2–5].Itisourstrongopinionthatactivecomparison
between PBPK and mechanism based models using the same
in vivo datasets can be helpful to further improve clinical
care but also provides guidance for more focused studies on
aspects of developmental physiology.
During the last 2-3 decades, hundreds of compound spe-
ciﬁc clinical pharmacology studies have been conducted to
investigate the impact of ontogeny on clinical pharmacology
in pediatric populations.
As clinical pharmacologists and neonatologists with
speciﬁc interest in developmental pharmacology, we would
like to raise awareness for the relevance of “rich data sets”
that contain both clinical characteristics and concentration-
time (pharmacokinetics) or concentration-eﬀect (pharma-
codynamics) proﬁles [6]. The description of a compound
speciﬁc pattern is beyond compound speciﬁc relevance
(“bottom-up”)[ 1–5]. The maturational patterns described
and the extent of the impact of covariates can subsequently
be applied to predict in vivo concentration-time proﬁles
for compounds that undergo similar routes of elimina-
tion. Through improved predictability, such maturational
mechanism-based models can serve to improve clinical care
and feasibility of clinical studies in neonates. The same
in vivo observations can also be used as a “bottom-up”
approachtolearnmoreaboutthematurationalpatterns,and
toguideresearchongapsintheknowledgeondevelopmental
anatomy and physiology.2 Journal of Biomedicine and Biotechnology
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Figure 1: Integration of in vivo datasets analyzed by mechanism-based and PBPK predictive models results in a switch from “explorative,
hypothesis-driven” to “conﬁrmative” approach in the ﬁeld of developmental physiology. This is illustrated for renal drug clearance in
neonates, which reﬂects glomerular ﬁltration rate (e.g., aminoglycosides) or a more complex pattern of known (glomerular ﬁltration rate,
protein binding) and still unknown (renal tubular transport ontogeny) (e.g., cefazolin) maturational processes.
The concept of a comparative approach using both
PBPK and mechanism-based models for drugs cleared by
renal elimination is illustrated in Figure 1. In the left
panelofFigure 1,amechanism-basedapproach(bottom-up:
description based on observations, subsequent validation) is
considered, in the right panel, a PBPK-based approach (top-
down: development of a PBPK model based on renal mat-
urational physiology data, that is, ontogeny of glomerular
ﬁltration rate [GFR] is applied). Based on mechanism-based
models,wedescribedcovariatesofamikacinandvancomycin
clearance in 531 neonates and documented that size, post-
menstrual age, growth restriction, and coadministration of
ibuprofen explained 85% of the interindividual variability in
clearance [7]. The same amikacin dataset has more recently
beenusedtovalidateaPBPKmodel(leftpanel,Figure 1)that
aimed to describe maturational GFR in (pre)term neonates
[8].
Both approaches should describe GFR ontogeny. How-
ever, when these PBPK-GFR models are subsequently used
to predict renal elimination clearance of compounds that do
not only depend on GFR, but also on protein binding and
renal tubular functions (e.g., cefazolin), the PBPK models
will fail because data on renal tubular ontogeny are not yet
available. In contrast, the use of mechanism-based models
to describe the covariates of cefazolin clearance in such a
dataset and comparison with the PBPK-GFR model may
unveil thresholds and patterns of renal tubular maturation
that can subsequently guide researchers to explore ontogeny
of renal tubular activity in speciﬁc subpopulations, resulting
in a similar conﬁrmatory instead of exploratory approach.
In conclusion, similar to PBPK models for clinical care
(top-down), mechanism-based models (bottom-up) and
comparisonbetweenboth approachesmayfurtherguideand
facilitate both clinical and fundamental research on develop-
mental physiology and anatomy [1–5]. Discrepancies serve
as indicators for “missing” links in our knowledge on matu-
rational anatomy or physiology (e.g., drug receptor activity,
receptor expression) and in this way may also shape funda-
mental research in the ﬁeld of developmental physiology. In
this way, PBPK models do not only hold the promise (top-
down) to be helpful in the clinical design, but may also serve
as indicators to perform developmental anatomy/physiology
research projects as “conﬁrmatory” instead of “exploratory.”
In this way, improved knowledge on developmental pharma-
cology does not only serve the individual clinician and the
patient, but can also improve focused fundamental research
onaspectsofdevelopmentalbiologythatarecurrentlyhardly
understood and diﬃcult to explore.
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